PRTC / PureTech Health remains undervalued after KarXCT deal, says broker

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC announced a lucrative royalty deal with Royalty Pharma for its KarXT drug, developed by Karuna more_horizontal

Shares in PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC jumped 10% after it agreed a US$500mln royalty deal, US$100mln of which will be paid more_horizontal

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based o more_horizontal

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based o more_horizontal

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based o more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 92% in PureTech Health PLC Sponsored ADR (PRTC). While the ef more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 92% in PureTech Health PLC Sponsored ADR (PRTC). While the ef more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 92% in PureTech Health PLC Sponsored ADR (PRTC). While the ef more_horizontal